Telo Genomics Corp ( (TSE:TELO) ) has issued an update.
Telo Genomics Corp has expanded its partnership with Trusted Health Advisors to enhance the commercialization of its diagnostic technologies over a six-month period. This collaboration will support various clinical programs, including those targeting multiple myeloma and prostate cancer, and involves the establishment of a clinical advisory board and collaboration with academic partners and reference labs. The partnership aims to advance Telo’s market positioning in oncology diagnostics by leveraging the expertise of THA’s experienced team.
More about Telo Genomics Corp
Telo Genomics Corp operates in the biotechnology industry, focusing on diagnostic technologies. The company specializes in developing diagnostic tools for identifying high-risk smoldering multiple myeloma and other cancer-related conditions, with a market focus on advancing clinical and research initiatives in oncology.
YTD Price Performance: -12.50%
Average Trading Volume: 60,038
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: C$10.48M
For an in-depth examination of TELO stock, go to TipRanks’ Stock Analysis page.